Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04221178 · ClinicalTrials.gov registry record

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

A clinical trial of Plasma Cell Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
50
Enrollment target
7
Study locations

NCT04221178: Active study of Plasma Cell Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04221178 is a study of Plasma Cell Myeloma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 50 participants, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (76% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04221178, a study of Plasma Cell Myeloma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
50 participants
Enrollment target
7
Study locations

Study Summary

This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy. The study will look at whether people currently on maintenance therapy can safely stop this treatment and continue with active surveillance instead while keeping their MRD-negative remission status for at least 1 year.

Primary Outcome

Maintaining a MRD-negative state for one year of enrolling on this study

Conditions Studied

Interventions

  • OTHER Cessation of continuous matinenace therapy

Study Locations (7)

New York

  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2020-01-03
Est. Completion 2027-01-03
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT04221178 still lists

NCT04221178 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Cessation of continuous matinenace therapy is the first listed.

NCT04221178 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT04221178 about?

NCT04221178 is a clinical study titled "Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission". This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy. The study will look at whether people currently on maintenance therapy can safely stop this treatment and continue wi...

What is the current status of trial NCT04221178?

This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2020-01-03. Estimated completion is 2027-01-03.

What conditions does trial NCT04221178 study?

This clinical trial studies the following conditions: Plasma Cell Myeloma.

What interventions are being tested in trial NCT04221178?

The interventions under investigation include: Cessation of continuous matinenace therapy (OTHER).

Who is sponsoring clinical trial NCT04221178?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04221178 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Plasma Cell Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04221178's enrollment target sits among peer trials

50 20th of 32 higher than 13 of 32 other Plasma Cell Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Plasma Cell Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04221178, the US trial registry maintained by the National Library of Medicine. NCT04221178 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.